L Strauss, R Hejal, G Galan, L Dixon and ER McFadden Jr
Department of Emergency Medicine, University Hospitals, Cleveland, Ohio 44106-5067, USA.

To determine the dose of albuterol required to terminate acute episodes of asthma, 92 acutely ill subjects received three doses of 2.5 mg each by nebulization every 20 min. Peak expiratory flow rates (PEFR) and signs and symptoms were serially monitored. A dose-response increase in pulmonary function was found, but only 66% of the subjects improved sufficiently to be sent home. Of these, 56% required < or = 5.0 mg of drug to reach the discharge threshold, whereas the remainder needed 7.5 mg. In 34% of participants, albuterol was ineffectual. These individuals were characterized by more severe obstruction at presentation, and after three doses of medication their PEFR still did not exceed 40% of the expected value. Further treatment in the emergency department (ED) or hospital was not immediately helpful, and these patients ultimately required 3.8 +/- 0.4 d of inpatient care to become asymptomatic. There were no discernible differences between responders and nonresponders in the type or quantity of medications used. However, the nonresponders had more severe disease as measured by recurrent hospitalizations and ED visits. This study demonstrates that, in emergency situations, albuterol does not relieve acute airway obstruction in all asthmatic individuals with equal efficacy. Two- thirds of patients are sensitive, and in these patients 5 to 7.5 mg of albuterol provides optimal treatment. In the remainder, albuterol, even in high doses, has little effect for days.

This article has been cited by other articles:

				A. El-Ekiaby, L. Brianas, M. E. Skowronski, A. J. Coreno, G. Galan, F. J. Kaeberlein, R. E. Seitz, K. D. Villaba, H. Dickey-White, and E. R. McFadden Jr. Impact of Race on the Severity of Acute Episodes of Asthma and Adrenergic Responsiveness Am. J. Respir. Crit. Care Med., September 1, 2006; 174(5): 508 - 513. [Abstract] [Full Text] [PDF]

				M. Peters-Golden, A. Swern, S. S. Bird, C. M. Hustad, E. Grant, and J. M. Edelman Influence of body mass index on the response to asthma controller agents. Eur. Respir. J., March 1, 2006; 27(3): 495 - 503. [Abstract] [Full Text] [PDF]

				E. R. McFadden Jr. Acute Severe Asthma Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 740 - 759. [Abstract] [Full Text] [PDF]

				M. M. Wilson, R. S. Irwin, A. E. Connolly, C. Linden, and M. M. Manno A Prospective Evaluation of the 1-Hour Decision Point for Admission Versus Discharge in Acute Asthma J Intensive Care Med, September 1, 2003; 18(5): 275 - 285. [Abstract] [PDF]

				C. A. Manthous Heliox for Status Asthmaticus? Chest, March 1, 2003; 123(3): 676 - 677. [Full Text] [PDF]

				C. A. Camargo Jr., H. A. Smithline, M.-P. Malice, S. A. Green, and T. F. Reiss A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 528 - 533. [Abstract] [Full Text] [PDF]

				R. K. Cydulka, E. R. McFadden, J. H. Sarver, and C. L. Emerman Comparison of Single 7.5-mg Dose Treatment vs Sequential Multidose 2.5-mg Treatments With Nebulized Albuterol in the Treatment of Acute Asthma Chest, December 1, 2002; 122(6): 1982 - 1987. [Abstract] [Full Text] [PDF]

				R. A. Silverman, H. Osborn, J. Runge, E. J. Gallagher, W. Chiang, J. Feldman, T. Gaeta, K. Freeman, B. Levin, N. Mancherje, et al. IV Magnesium Sulfate in the Treatment of Acute Severe Asthma* : A Multicenter Randomized Controlled Trial Chest, August 1, 2002; 122(2): 489 - 497. [Abstract] [Full Text] [PDF]

				G. J. Rodrigo and C. Rodrigo Continuous vs Intermittent {beta}-Agonists in the Treatment of Acute Adult Asthma* : A Systematic Review With Meta-analysis Chest, July 1, 2002; 122(1): 160 - 165. [Abstract] [Full Text] [PDF]

				G. J. Rodrigo and C. Rodrigo The Role of Anticholinergics in Acute Asthma Treatment* : An Evidence-Based Evaluation Chest, June 1, 2002; 121(6): 1977 - 1987. [Abstract] [Full Text] [PDF]

				J. P. Kress, I. Noth, B. K. Gehlbach, N. Barman, A. S. Pohlman, A. Miller, S. Morgan, and J. B. Hall The Utility of Albuterol Nebulized with Heliox during Acute Asthma Exacerbations Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1317 - 1321. [Abstract] [Full Text] [PDF]

				H. W. Kelly The Management of Acute Severe Asthma Journal of Pharmacy Practice, April 1, 2001; 14(2): 91 - 107. [Abstract] [PDF]

				R J Dockhorn, R A Baumgartner, J A Leff, M Noonan, K Vandormael, W Stricker, D E Weinland, and T F Reiss Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients Thorax, April 1, 2000; 55(4): 260 - 265. [Abstract] [Full Text]

				J. W. Chien, R. Ciufo, R. Novak, M. Skowronski, J. Nelson, A. Coreno, and E. R. McFadden Jr. Uncontrolled Oxygen Administration and Respiratory Failure in Acute Asthma Chest, March 1, 2000; 117(3): 728 - 733. [Abstract] [Full Text] [PDF]

				G. Rodrigo and C. Rodrigo Corticosteroids in the Emergency Department Therapy of Acute Adult Asthma: An Evidence-Based Evaluation Chest, August 1, 1999; 116(2): 285 - 295. [Abstract] [Full Text] [PDF]

				C. L. Emerman, P. G. Woodruff, R. K. Cydulka, M. A. Gibbs, C. V. Pollack Jr., and C. A. Camargo Jr. Prospective Multicenter Study of Relapse Following Treatment for Acute Asthma Among Adults Presenting to the Emergency Department Chest, April 1, 1999; 115(4): 919 - 927. [Abstract] [Full Text] [PDF]

				C. L. Emerman, R. K. Cydulka, and E. R. McFadden Comparison of 2.5 vs 7.5 mg of Inhaled Albuterol in the Treatment of Acute Asthma Chest, January 1, 1999; 115(1): 92 - 96. [Abstract] [Full Text] [PDF]

				E. R. McFadden Jr. Inhaled Glucocorticoids and Acute Asthma . Therapeutic Breakthrough or Nonspecific Effect? Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 677 - 678. [Full Text] [PDF]